Quantum BioPharma Ltd. Operating Expense
Quantum BioPharma Ltd. (QNTM) reported Operating Expense of $15.30 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2026-03-26
- Quantum BioPharma Ltd. operating expense for the quarter ending 2025-12-31 was $2.37M, a 61.97% decline year-over-year.
- Quantum BioPharma Ltd. operating expense for the quarter ending 2025-09-30 was $4.68M, a 11.89% increase year-over-year.
- Quantum BioPharma Ltd. operating expense for the quarter ending 2025-06-30 was $4.85M, a 40.41% increase year-over-year.
- Quantum BioPharma Ltd. operating expense for the quarter ending 2025-03-31 was $3.40M, a 50.50% increase year-over-year.
| Period end | Operating Expense 3 month | Operating Expense 6 month | Operating Expense 9 month | Operating Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.37M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $7.05M derived: sum of 2 quarters · filed 2026-03-26 | $11.90M derived: sum of 3 quarters · filed 2026-03-26 | $15.30M 20-F · filed 2026-03-26 |
| 2025-09-30 | $4.68M 6-K · filed 2025-11-06 | $9.53M derived: sum of 2 quarters · filed 2025-11-06 | $12.93M 6-K · filed 2025-11-06 | $19.17M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $4.85M 6-K · filed 2025-08-07 | $8.25M 6-K · filed 2025-08-07 | $14.49M derived: sum of 3 quarters · filed 2026-03-26 | $18.67M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $3.40M 6-K/A · filed 2025-06-16 | $9.64M derived: sum of 2 quarters · filed 2026-03-26 | $13.82M derived: sum of 3 quarters · filed 2026-03-26 | $17.28M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $6.24M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $10.42M derived: sum of 2 quarters · filed 2026-03-26 | $13.88M derived: sum of 3 quarters · filed 2026-03-26 | $16.14M 20-F · filed 2026-03-26 |
| 2024-09-30 | $4.18M 6-K · filed 2025-11-06 | $7.64M derived: sum of 2 quarters · filed 2025-11-06 | $9.90M 6-K · filed 2025-11-06 | $11.70M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $3.46M 6-K · filed 2025-08-07 | $5.71M 6-K · filed 2025-08-07 | $7.52M derived: sum of 3 quarters · filed 2026-03-26 | $10.83M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $2.26M 6-K/A · filed 2025-06-16 | $4.06M derived: sum of 2 quarters · filed 2026-03-26 | $7.37M derived: sum of 3 quarters · filed 2026-03-26 | $16.20M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $1.80M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $5.11M derived: sum of 2 quarters · filed 2026-03-26 | $13.94M derived: sum of 3 quarters · filed 2026-03-26 | $23.79M 20-F · filed 2026-03-26 |
| 2023-09-30 | $3.31M 6-K · filed 2024-11-12 | $12.14M derived: sum of 2 quarters · filed 2024-11-12 | $21.99M 6-K · filed 2024-11-12 | |
| 2023-06-30 | $8.83M 6-K/A · filed 2024-08-19 | $18.68M 6-K/A · filed 2024-08-19 | ||
| 2022-12-31 | $27.43M 20-F/A · filed 2025-03-31 | |||
| 2021-12-31 | $33.74M 20-F · filed 2024-04-02 |